NB012689
TRAF-1 Antibody (TRAF1/3298) - Azide and BSA Free, Novus Biologicals™
Manufacturer: Novus Biologicals
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | NB012689-Each-of-1 | In Stock | ₹ 55,271.76 |
NB012689 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 55,271.76
GST (18%): ₹ 9,948.917
Total Price: ₹ 65,220.677
Antigen
TRAF-1
Classification
Monoclonal
Concentration
1 mg/mL
Dilution
Immunohistochemistry 1-2 ug/ml, Immunohistochemistry-Paraffin 1-2 ug/ml, Protein Array
Gene Alias
EBI6MGC:10353, Epstein-Bar virus-induced protein 6, Epstein-Barr virus-induced protein 6, TNF receptor-associated factor 1
Host Species
Mouse
Purification Method
Protein A or G purified
Regulatory Status
RUO
Primary or Secondary
Primary
Target Species
Human
Form
Purified
Applications
Immunohistochemistry, Immunohistochemistry (Paraffin), Peptide Array
Clone
TRAF1/3298
Conjugate
Unconjugated
Formulation
10 mM PBS with No Preservative
Gene Symbols
TRAF1
Immunogen
Recombinant fragment of human TRAF-1 protein (around aa 73-219) (exact sequence is proprietary) (Uniprot: Q13077)
Quantity
100 μg
Research Discipline
Apoptosis, Cancer, Cytokine Research
Test Specificity
This monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP an
Content And Storage
Aliquot and store at -20°C or -80°C. Avoid freeze-thaw cycles.
Isotype
IgG2b κ
Related Products
Description
- TRAF-1 Monoclonal specifically detects TRAF-1 in Human samples
- It is validated for Immunohistochemistry, Immunohistochemistry-Paraffin, Protein Array.
Compare Similar Items
Show Difference
Antigen: TRAF-1
Classification: Monoclonal
Concentration: 1 mg/mL
Dilution: Immunohistochemistry 1-2 ug/ml, Immunohistochemistry-Paraffin 1-2 ug/ml, Protein Array
Gene Alias: EBI6MGC:10353, Epstein-Bar virus-induced protein 6, Epstein-Barr virus-induced protein 6, TNF receptor-associated factor 1
Host Species: Mouse
Purification Method: Protein A or G purified
Regulatory Status: RUO
Primary or Secondary: Primary
Target Species: Human
Form: Purified
Applications: Immunohistochemistry, Immunohistochemistry (Paraffin), Peptide Array
Clone: TRAF1/3298
Conjugate: Unconjugated
Formulation: 10 mM PBS with No Preservative
Gene Symbols: TRAF1
Immunogen: Recombinant fragment of human TRAF-1 protein (around aa 73-219) (exact sequence is proprietary) (Uniprot: Q13077)
Quantity: 100 μg
Research Discipline: Apoptosis, Cancer, Cytokine Research
Test Specificity: This monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP an
Content And Storage: Aliquot and store at -20°C or -80°C. Avoid freeze-thaw cycles.
Isotype: IgG2b κ
Antigen:
TRAF-1
Classification:
Monoclonal
Concentration:
1 mg/mL
Dilution:
Immunohistochemistry 1-2 ug/ml, Immunohistochemistry-Paraffin 1-2 ug/ml, Protein Array
Gene Alias:
EBI6MGC:10353, Epstein-Bar virus-induced protein 6, Epstein-Barr virus-induced protein 6, TNF receptor-associated factor 1
Host Species:
Mouse
Purification Method:
Protein A or G purified
Regulatory Status:
RUO
Primary or Secondary:
Primary
Target Species:
Human
Form:
Purified
Applications:
Immunohistochemistry, Immunohistochemistry (Paraffin), Peptide Array
Clone:
TRAF1/3298
Conjugate:
Unconjugated
Formulation:
10 mM PBS with No Preservative
Gene Symbols:
TRAF1
Immunogen:
Recombinant fragment of human TRAF-1 protein (around aa 73-219) (exact sequence is proprietary) (Uniprot: Q13077)
Quantity:
100 μg
Research Discipline:
Apoptosis, Cancer, Cytokine Research
Test Specificity:
This monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP an
Content And Storage:
Aliquot and store at -20°C or -80°C. Avoid freeze-thaw cycles.
Isotype:
IgG2b κ
Antigen: TRAF-1
Classification: Monoclonal
Concentration: __
Dilution: Immunohistochemistry, Immunohistochemistry-Paraffin
Gene Alias: EBI6MGC:10353, Epstein-Bar virus-induced protein 6, Epstein-Barr virus-induced protein 6, TNF receptor-associated factor 1
Host Species: Mouse
Purification Method: Protein A or G purified
Regulatory Status: RUO
Primary or Secondary: Primary
Target Species: Human
Form: __
Applications: Immunohistochemistry, Immunohistochemistry (Paraffin)
Clone: TRAF1/3298
Conjugate: Alexa Fluor 405
Formulation: 50mM Sodium Borate with 0.05% Sodium Azide
Gene Symbols: TRAF1
Immunogen: Recombinant fragment of human TRAF-1 protein (around aa 73-219) (exact sequence is proprietary) (Uniprot: Q13077)
Quantity: 0.1 mL
Research Discipline: Apoptosis, Cancer, Cytokine Research
Test Specificity: This monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)-associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7%). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations.
Content And Storage: Store at 4°C in the dark.
Isotype: IgG2b κ
Antigen:
TRAF-1
Classification:
Monoclonal
Concentration:
__
Dilution:
Immunohistochemistry, Immunohistochemistry-Paraffin
Gene Alias:
EBI6MGC:10353, Epstein-Bar virus-induced protein 6, Epstein-Barr virus-induced protein 6, TNF receptor-associated factor 1
Host Species:
Mouse
Purification Method:
Protein A or G purified
Regulatory Status:
RUO
Primary or Secondary:
Primary
Target Species:
Human
Form:
__
Applications:
Immunohistochemistry, Immunohistochemistry (Paraffin)
Clone:
TRAF1/3298
Conjugate:
Alexa Fluor 405
Formulation:
50mM Sodium Borate with 0.05% Sodium Azide
Gene Symbols:
TRAF1
Immunogen:
Recombinant fragment of human TRAF-1 protein (around aa 73-219) (exact sequence is proprietary) (Uniprot: Q13077)
Quantity:
0.1 mL
Research Discipline:
Apoptosis, Cancer, Cytokine Research
Test Specificity:
This monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)-associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7%). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations.
Content And Storage:
Store at 4°C in the dark.
Isotype:
IgG2b κ
Antigen: TRAF-1
Classification: Monoclonal
Concentration: __
Dilution: Immunohistochemistry, Immunohistochemistry-Paraffin
Gene Alias: EBI6MGC:10353, Epstein-Bar virus-induced protein 6, Epstein-Barr virus-induced protein 6, TNF receptor-associated factor 1
Host Species: Mouse
Purification Method: Protein A or G purified
Regulatory Status: RUO
Primary or Secondary: Primary
Target Species: Human
Form: __
Applications: Immunohistochemistry, Immunohistochemistry (Paraffin)
Clone: TRAF1/3298
Conjugate: Alexa Fluor 488
Formulation: 50mM Sodium Borate with 0.05% Sodium Azide
Gene Symbols: TRAF1
Immunogen: Recombinant fragment of human TRAF-1 protein (around aa 73-219) (exact sequence is proprietary) (Uniprot: Q13077)
Quantity: 0.1 mL
Research Discipline: Apoptosis, Cancer, Cytokine Research
Test Specificity: This monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)-associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7%). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations.
Content And Storage: Store at 4°C in the dark.
Isotype: IgG2b κ
Antigen:
TRAF-1
Classification:
Monoclonal
Concentration:
__
Dilution:
Immunohistochemistry, Immunohistochemistry-Paraffin
Gene Alias:
EBI6MGC:10353, Epstein-Bar virus-induced protein 6, Epstein-Barr virus-induced protein 6, TNF receptor-associated factor 1
Host Species:
Mouse
Purification Method:
Protein A or G purified
Regulatory Status:
RUO
Primary or Secondary:
Primary
Target Species:
Human
Form:
__
Applications:
Immunohistochemistry, Immunohistochemistry (Paraffin)
Clone:
TRAF1/3298
Conjugate:
Alexa Fluor 488
Formulation:
50mM Sodium Borate with 0.05% Sodium Azide
Gene Symbols:
TRAF1
Immunogen:
Recombinant fragment of human TRAF-1 protein (around aa 73-219) (exact sequence is proprietary) (Uniprot: Q13077)
Quantity:
0.1 mL
Research Discipline:
Apoptosis, Cancer, Cytokine Research
Test Specificity:
This monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)-associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7%). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations.
Content And Storage:
Store at 4°C in the dark.
Isotype:
IgG2b κ
Antigen: TRAF-1
Classification: Monoclonal
Concentration: __
Dilution: Immunohistochemistry, Immunohistochemistry-Paraffin
Gene Alias: EBI6MGC:10353, Epstein-Bar virus-induced protein 6, Epstein-Barr virus-induced protein 6, TNF receptor-associated factor 1
Host Species: Mouse
Purification Method: Protein A or G purified
Regulatory Status: RUO
Primary or Secondary: Primary
Target Species: Human
Form: __
Applications: Immunohistochemistry, Immunohistochemistry (Paraffin)
Clone: TRAF1/3298
Conjugate: Alexa Fluor 647
Formulation: 50mM Sodium Borate with 0.05% Sodium Azide
Gene Symbols: TRAF1
Immunogen: Recombinant fragment of human TRAF-1 protein (around aa 73-219) (exact sequence is proprietary) (Uniprot: Q13077)
Quantity: 0.1 mL
Research Discipline: Apoptosis, Cancer, Cytokine Research
Test Specificity: This monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)-associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7%). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations.
Content And Storage: Store at 4°C in the dark.
Isotype: IgG2b κ
Antigen:
TRAF-1
Classification:
Monoclonal
Concentration:
__
Dilution:
Immunohistochemistry, Immunohistochemistry-Paraffin
Gene Alias:
EBI6MGC:10353, Epstein-Bar virus-induced protein 6, Epstein-Barr virus-induced protein 6, TNF receptor-associated factor 1
Host Species:
Mouse
Purification Method:
Protein A or G purified
Regulatory Status:
RUO
Primary or Secondary:
Primary
Target Species:
Human
Form:
__
Applications:
Immunohistochemistry, Immunohistochemistry (Paraffin)
Clone:
TRAF1/3298
Conjugate:
Alexa Fluor 647
Formulation:
50mM Sodium Borate with 0.05% Sodium Azide
Gene Symbols:
TRAF1
Immunogen:
Recombinant fragment of human TRAF-1 protein (around aa 73-219) (exact sequence is proprietary) (Uniprot: Q13077)
Quantity:
0.1 mL
Research Discipline:
Apoptosis, Cancer, Cytokine Research
Test Specificity:
This monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)-associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7%). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations.
Content And Storage:
Store at 4°C in the dark.
Isotype:
IgG2b κ